Skip to main content

Table 4 Prevalence and incidence of gametocytes during the study (ITT population)

From: Therapeutic efficacy and safety of dihydroartemisinin-piperaquine versus artesunate-mefloquine in uncomplicated Plasmodium falciparum malaria in India

 

DP n/N (%)

A + M n/N (%)

Gametocyte prevalence 1

Day 7

7/98 (7.1)

0/46 (0.0)

Day 14

5/94 (5.3)

0/44 (0.0)

Day 28

0/89 (0.0)

0/42 (0.0)

Day 42

0/85 (0.0)

0/41 (0.0)

Day 63

0/81 (0.0)

0/41 (0.0)

Overall (day 7 - day 63)

9/98 (9.2)

0/46 (0.0)

Gametocyte incidence 2

Day 7

7/98 (7.14)

0/46 (0.0)

Day 14

2/94 (2.13)

0/44 (0.0)

Day 28

0/89 (0.0)

0/42 (0.0)

Day 42

0/85 (0.0)

0/41 (0.0)

Day 63

0/81 (0.0)

0/41 (0.0)

Person-gametocyte-weeks 3

18/814 (22.1)

0/391 (0.0)

  1. DP = dihydroartemisinin-piperaquine; A + M = artesunate-mefloquine.
  2. 1Calculated, at a given time, as number of patients with gametocytes at that time divided by the number of patients having reached that time;
  3. 2Calculated, at a given time interval, as number of new patients with gametocytes in that interval divided by the number of patients having reached the end of that interval;
  4. 3Calculated as number of weeks in which blood slides were positive for gametocytes during the whole study (up to a maximum duration of 70 days) divided by the number of all follow-up weeks and expressed per 1,000 person-weeks.